Lupin Limited (NSE:LUPIN)
India
· Delayed Price · Currency is INR | Market Cap | 925.18B |
| Revenue (ttm) | 220.02B |
| Net Income (ttm) | 28.69B |
| Shares Out | n/a |
| EPS (ttm) | 62.70 |
| PE Ratio | 32.25 |
| Forward PE | n/a |
| Dividend | 8.00 (0.39%) |
| Ex-Dividend Date | Jul 16, 2024 |
| Volume | 828,316 |
| Average Volume | 773,992 |
| Open | 2,044.85 |
| Previous Close | 2,018.80 |
| Day's Range | 1,993.75 - 2,044.85 |
| 52-Week Range | 1,493.30 - 2,402.90 |
| Beta | 0.58 |
| RSI | 49.11 |
| Earnings Date | May 6, 2025 |
About Lupin
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women’s health, central nerv... [Read more]
Financial Performance
In 2023, Lupin's revenue was 200.11 billion, an increase of 20.25% compared to the previous year's 166.42 billion. Earnings were 19.14 billion, an increase of 345.15%.
Financial StatementsNews
Lupin Digital Health launches post-procedure home care guide in collaboration with American College of Cardiology
Lupin Digital Health (LDH), the digital therapeutics arm of Lupin Limited, has launched a comprehensive Post-Procedure Home-Based Care Guide to support cardiac patients in their recovery journey after...
Lupin receives U.S. FDA approval for 10 mg Amifampridine Tablets
Global pharmaceutical leader Lupin Limited has secured tentative approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Amifampridine Tablets, 10 mg. This approval paves the wa...
Lupin share price surges over 1.50% after US launch of Rivaroxaban, brokerages bullish
Shares of Lupin Ltd. (NSE: LUPIN) surged 1.57% to ₹2,061.80 in early trade today following the company’s US launch of generic Rivaroxaban 2.5mg tablets (gXarelto). The stock opened at ₹2,049.80, hit a...
Lupin launches FDA-approved Rivaroxaban Tablets USP, 2.5 mg in the US
Global pharmaceutical leader Lupin Limited has announced the launch of Rivaroxaban Tablets USP, 2.5 mg in the U.S. market. This follows the final approval of its Abbreviated New Drug Application (ANDA...
Lupin shares surge 2.35% as US FDA issues Establishment Inspection Report (EIR) for Somerset facility
Shares of Lupin Ltd surged over 2% on February 24 after the company announced that it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its Som...
Lupin’s Somerset plant gets FDA approval following successful inspection
Global pharmaceutical giant Lupin Limited has announced that its Somerset, New Jersey manufacturing facility has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administ...
Lupin gets USFDA nod for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03%
Lupin Limited has secured approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% (21 mcg/...
Lupin and Natco Pharma gets USFDA nod for Generic Bosentan tablets
Lupin Limited (Lupin) and its alliance partner Natco Pharma Limited (Natco) have received approval from the U.S. Food and Drug Administration (FDA) for Natco’s Abbreviated New Drug Application (ANDA) ...
Lupin completes acquisition of 42.61% stake in Sunsure Solarpark
Lupin Limited has announced the successful acquisition of a 42.61% equity stake in Sunsure Solarpark Seventeen Private Limited, as part of its strategic investment in renewable energy initiatives. The...
Lupin acquires Huminsulin from Eli Lilly to strengthen its diabetes portfolio
Lupin Limited, a global pharmaceutical leader, announced the acquisition of the Huminsulin® range from Eli Lilly and Company to enhance its diabetes treatment portfolio in India. The acquisition inclu...
Lupin confirms tentative US FDA approval for Type-2 Diabetes drug Janumet generic
Lupin Limited has clarified reports regarding a recent news item about the company receiving US FDA approval. The company confirmed that it has received tentative approval from the US FDA for its gene...
Lupin and NAPCON hold walkathon for lung health
Lupin Limited and the National Conference of Pulmonary Diseases (NAPCON) 2024 hosted the second ‘A Step Towards Healthy Lungs Walkathon’ at the Raceco.
Lupin and Aurobindo Pharma shares in focus on positive US generics outlook; Macquarie sees potential rally
Lupin Ltd and Aurobindo Pharma Ltd stocks moved upwards in early trade, with Lupin’s shares trading at ₹2,194.50, marking a 0.58% increase, while Aurobindo Pharma stood at ₹1,399.50, up by 0.18% as of...
Lupin launches first generic of Pred Forte in United States
Global pharma major Lupin Limited (Lupin) has recently informed exchanges that the company has launched the first generic version of Pred Forte (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in ...
Lupin signs non-exclusive patent license agreement with Takeda to commercialize Vonoprazan in India
Lupin Limited has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited to commercialize Vonoprazan Tablets in India. Under this agreement, Lupin will market...